Hedgehog signaling and urological cancers

Area of Science:

• Oncology
• Molecular Biology
• Urology

Background:

• Aberrant Hedgehog (Hh) signaling is implicated in various cancers, yet therapeutic strategies for urological malignancies remain limited due to incompletely understood progression mechanisms.
• Vismodegib, an Hh pathway inhibitor, is approved for basal cell carcinoma and shows potential for other cancers. Cholecalciferol (vitamin D3) inhibits Shh-Gli signaling and may offer growth inhibitory effects in renal cancer.
• Preclinical prostate cancer data indicate Hh pathway suppression can reduce invasion and metastasis but may lead to acquired drug resistance with prolonged use.

Purpose of the Study:

• To review recent trends in Hedgehog (Hh) signaling activation studies within urological cancers.
• To explore potential clinical applications of targeting Hh signaling in urological malignancies.
• To discuss the anti-tumor effects and safety of Hh pathway inhibitors, including supplementary therapies.

Main Methods:

• Literature review of studies investigating Hh signaling in urological cancers.
• Analysis of preclinical data on Hh pathway inhibitors, including vismodegib and cholecalciferol.
• Examination of gene expression data for Hh pathway components and targets in urothelial tumors.

Main Results:

• Hedgehog (Hh) signaling pathway activation is observed in several hematological and solid cancers.
• Overexpression of Shh is noted in 96% of non-muscle invasive bladder cancer and 52% of muscle invasive bladder cancer samples.
• Combining Hh inhibitors with chemotherapy or radiation may enhance treatment efficacy and mitigate acquired drug resistance.

Conclusions:

• Targeting the Hh signaling pathway presents a potential therapeutic strategy for urological cancers.
• Cholecalciferol (vitamin D3) demonstrates potential as a supplementary therapy for renal cancer by inhibiting Shh-Gli signaling.
• Further research is needed to establish the anti-tumor effects and safety of Hh pathway inhibitors in urological tumors, with combination therapies showing promise for overcoming resistance.